{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,7]],"date-time":"2026-06-07T00:11:41Z","timestamp":1780791101021,"version":"3.54.1"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2025,10,20]],"date-time":"2025-10-20T00:00:00Z","timestamp":1760918400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,10,20]],"date-time":"2025-10-20T00:00:00Z","timestamp":1760918400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int Urol Nephrol"],"DOI":"10.1007\/s11255-025-04776-9","type":"journal-article","created":{"date-parts":[[2025,10,20]],"date-time":"2025-10-20T13:16:27Z","timestamp":1760966187000},"page":"1775-1782","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Serum PCSK9 level as a potential biomarker relating to age, cholesterol and predicting major adverse cardiovascular event risk in hemodialysis patients"],"prefix":"10.1007","volume":"58","author":[{"given":"Yunxia","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenxiu","family":"Chai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Panpan","family":"Cai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ye","family":"Xin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianbo","family":"Shao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,10,20]]},"reference":[{"issue":"1","key":"4776_CR1","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1053\/j.semvascsurg.2021.02.010","volume":"34","author":"R Gupta","year":"2021","unstructured":"Gupta R, Woo K, Yi JA (2021) Epidemiology of end-stage kidney disease. Semin Vasc Surg 34(1):71\u201378. https:\/\/doi.org\/10.1053\/j.semvascsurg.2021.02.010","journal-title":"Semin Vasc Surg"},{"issue":"2","key":"4776_CR2","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1159\/000514550","volume":"52","author":"JS Thurlow","year":"2021","unstructured":"Thurlow JS, Joshi M, Yan G, Norris KC, Agodoa LY, Yuan CM, Nee R (2021) Global epidemiology of end-stage kidney disease and disparities in kidney replacement therapy. Am J Nephrol 52(2):98\u2013107. https:\/\/doi.org\/10.1159\/000514550","journal-title":"Am J Nephrol"},{"issue":"6","key":"4776_CR3","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1038\/s41581-022-00542-7","volume":"18","author":"AK Bello","year":"2022","unstructured":"Bello AK, Okpechi IG, Osman MA, Cho Y, Htay H, Jha V, Wainstein M, Johnson DW (2022) Epidemiology of haemodialysis outcomes. Nat Rev Nephrol 18(6):378\u2013395. https:\/\/doi.org\/10.1038\/s41581-022-00542-7","journal-title":"Nat Rev Nephrol"},{"issue":"4","key":"4776_CR4","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1053\/j.semvascsurg.2024.10.001","volume":"37","author":"ZS Pallister","year":"2024","unstructured":"Pallister ZS, Chung J (2024) The effects of hemodialysis on the cardiovascular system. Semin Vasc Surg 37(4):419\u2013426. https:\/\/doi.org\/10.1053\/j.semvascsurg.2024.10.001","journal-title":"Semin Vasc Surg"},{"issue":"4","key":"4776_CR5","doi-asserted-by":"publisher","first-page":"628","DOI":"10.5603\/cj.92167","volume":"31","author":"Z Heleniak","year":"2024","unstructured":"Heleniak Z, Bohdan M, Gruchala M, Debska-Slizien A (2024) Heart failure biomarkers in hemodialysis patients. Cardiol J 31(4):628\u2013636. https:\/\/doi.org\/10.5603\/cj.92167","journal-title":"Cardiol J"},{"key":"4776_CR6","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines13020367","author":"EM Davies","year":"2025","unstructured":"Davies EM, Buckley BJR, Austin P, Lip GYH, Rao A, McDowell G (2025) Cardiac biomarkers predict major adverse cardiac events (MACE) in incident haemodialysis patients: results from a global federated database. Biomedicines. https:\/\/doi.org\/10.3390\/biomedicines13020367","journal-title":"Biomedicines"},{"issue":"8","key":"4776_CR7","doi-asserted-by":"publisher","first-page":"2755","DOI":"10.1007\/s11255-024-04026-4","volume":"56","author":"I Bellos","year":"2024","unstructured":"Bellos I, Marinaki S, Lagiou P, Benetou V (2024) Association of serum galectin-3 levels with mortality and cardiovascular disease outcomes in hemodialysis patients: a systematic review and dose-response meta-analysis. Int Urol Nephrol 56(8):2755\u20132767. https:\/\/doi.org\/10.1007\/s11255-024-04026-4","journal-title":"Int Urol Nephrol"},{"key":"4776_CR8","doi-asserted-by":"publisher","first-page":"156064","DOI":"10.1016\/j.metabol.2024.156064","volume":"163","author":"A Ajoolabady","year":"2025","unstructured":"Ajoolabady A, Pratico D, Mazidi M, Davies IG, Lip GYH, Seidah N, Libby P, Kroemer G, Ren J (2025) PCSK9 in metabolism and diseases. Metabolism 163:156064. https:\/\/doi.org\/10.1016\/j.metabol.2024.156064","journal-title":"Metabolism"},{"issue":"1","key":"4776_CR9","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1038\/s41392-023-01690-3","volume":"9","author":"X Bao","year":"2024","unstructured":"Bao X, Liang Y, Chang H, Cai T, Feng B, Gordon K, Zhu Y, Shi H, He Y, Xie L (2024) Targeting proprotein convertase subtilisin\/kexin type 9 (PCSK9): from bench to bedside. Signal Transduct Target Ther 9(1):13. https:\/\/doi.org\/10.1038\/s41392-023-01690-3","journal-title":"Signal Transduct Target Ther"},{"key":"4776_CR10","doi-asserted-by":"publisher","first-page":"639727","DOI":"10.3389\/fcvm.2021.639727","volume":"8","author":"A Luquero","year":"2021","unstructured":"Luquero A, Badimon L, Borrell-Pages M (2021) Pcsk9 functions in atherosclerosis are not limited to plasmatic LDL-cholesterol regulation. Front Cardiovasc Med 8:639727. https:\/\/doi.org\/10.3389\/fcvm.2021.639727","journal-title":"Front Cardiovasc Med"},{"issue":"1","key":"4776_CR11","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1007\/s11357-023-01003-0","volume":"46","author":"A Csiszar","year":"2024","unstructured":"Csiszar A, Tarantini S, Yabluchanskiy A, Ungvari Z (2024) PCSK9: an emerging player in cardiometabolic aging and its potential as a therapeutic target and biomarker. Geroscience 46(1):257\u2013263. https:\/\/doi.org\/10.1007\/s11357-023-01003-0","journal-title":"Geroscience"},{"key":"4776_CR12","doi-asserted-by":"publisher","DOI":"10.14336\/AD.2024.1713","author":"D Tan","year":"2025","unstructured":"Tan D, Yang X, Yang J, Fan G, Xiong G (2025) Pcsk9 in vascular aging and age-related diseases. Aging Dis. https:\/\/doi.org\/10.14336\/AD.2024.1713","journal-title":"Aging Dis"},{"key":"4776_CR13","doi-asserted-by":"publisher","DOI":"10.1155\/2024\/5830491","author":"B Bagheri","year":"2024","unstructured":"Bagheri B, Khatibiyan Feyzabadi Z, Nouri A, Azadfallah A, Mahdizade Ari M, Hemmati M, Darban M, Alavi Toosi P, Banihashemian SZ (2024) Atherosclerosis and toll-like receptor4 (TLR4), lectin-like oxidized low-density lipoprotein-1 (LOX-1), and proprotein convertase subtilisin\/kexin type9 (PCSK9). Mediators Inflamm. https:\/\/doi.org\/10.1155\/2024\/5830491","journal-title":"Mediators Inflamm"},{"issue":"1","key":"4776_CR14","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1186\/s12944-021-01610-w","volume":"21","author":"J Peng","year":"2022","unstructured":"Peng J, Liu MM, Jin JL, Cao YX, Guo YL, Wu NQ, Zhu CG, Dong Q, Sun J, Xu RX, Li JJ (2022) NAFLD fibrosis score is correlated with PCSK9 and improves outcome prediction of PCSK9 in patients with chest pain: a cohort study. Lipids Health Dis 21(1):3. https:\/\/doi.org\/10.1186\/s12944-021-01610-w","journal-title":"Lipids Health Dis"},{"key":"4776_CR15","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1016\/j.amjcard.2020.07.032","volume":"133","author":"IJ Choi","year":"2020","unstructured":"Choi IJ, Lim S, Lee D, Lee WJ, Lee KY, Kim MJ, Jeon DS (2020) Relation of proprotein convertase subtilisin\/kexin type 9 to cardiovascular outcomes in patients undergoing percutaneous coronary intervention. Am J Cardiol 133:54\u201360. https:\/\/doi.org\/10.1016\/j.amjcard.2020.07.032","journal-title":"Am J Cardiol"},{"issue":"25","key":"4776_CR16","doi-asserted-by":"publisher","first-page":"2313","DOI":"10.1056\/NEJMoa2113380","volume":"385","author":"AK Singh","year":"2021","unstructured":"Singh AK, Carroll K, McMurray JJV, Solomon S, Jha V, Johansen KL, Lopes RD, Macdougall IC, Obrador GT, Waikar SS, Wanner C, Wheeler DC, Wiecek A, Blackorby A, Cizman B, Cobitz AR, Davies R, DiMino TL, Kler L, Meadowcroft AM, Taft L, Perkovic V, Group A-NS (2021) Daprodustat for the treatment of anemia in patients not undergoing dialysis. N Engl J Med 385(25):2313\u20132324. https:\/\/doi.org\/10.1056\/NEJMoa2113380","journal-title":"N Engl J Med"},{"issue":"7","key":"4776_CR17","doi-asserted-by":"publisher","first-page":"1298","DOI":"10.1093\/ndt\/gfaa357","volume":"36","author":"M Evans","year":"2020","unstructured":"Evans M, Xu H, Rydell H, Prutz KG, Lindholm B, Stendahl M, Segelmark M, Carrero JJ (2020) Association between implementation of novel therapies and improved survival in patients starting hemodialysis: the Swedish Renal Registry 2006\u20132015. Nephrol Dial Transplant 36(7):1298\u20131306. https:\/\/doi.org\/10.1093\/ndt\/gfaa357","journal-title":"Nephrol Dial Transplant"},{"issue":"5","key":"4776_CR18","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1007\/s10741-024-10409-7","volume":"29","author":"M Dutka","year":"2024","unstructured":"Dutka M, Zimmer K, Cwiertnia M, Ilczak T, Bobinski R (2024) The role of PCSK9 in heart failure and other cardiovascular diseases-mechanisms of action beyond its effect on LDL cholesterol. Heart Fail Rev 29(5):917\u2013937. https:\/\/doi.org\/10.1007\/s10741-024-10409-7","journal-title":"Heart Fail Rev"},{"issue":"36","key":"4776_CR19","doi-asserted-by":"publisher","first-page":"7446","DOI":"10.2174\/0929867328666210531150302","volume":"28","author":"Q Xiang","year":"2021","unstructured":"Xiang Q, Liu WF, Zeng JL, Deng YM, Peng J, Liu HT, Ren Z, Jiang ZS, Liu LS, Tang ZH (2021) Effect of PCSK9 on vascular smooth muscle cell functions: a new player in atherosclerosis. Curr Med Chem 28(36):7446\u20137460. https:\/\/doi.org\/10.2174\/0929867328666210531150302","journal-title":"Curr Med Chem"},{"key":"4776_CR20","doi-asserted-by":"publisher","DOI":"10.3390\/ijms22115880","author":"C Barale","year":"2021","unstructured":"Barale C, Melchionda E, Morotti A, Russo I (2021) PCSK9 biology and its role in atherothrombosis. Int J Mol Sci. https:\/\/doi.org\/10.3390\/ijms22115880","journal-title":"Int J Mol Sci"},{"issue":"1","key":"4776_CR21","doi-asserted-by":"publisher","first-page":"2215880","DOI":"10.1080\/0886022X.2023.2215880","volume":"45","author":"Z Feng","year":"2023","unstructured":"Feng Z, Liao X, Zhang H, Peng J, Huang Z, Yi B (2023) Increased serum PCSK9 levels are associated with renal function impairment in patients with type 2 diabetes mellitus. Ren Fail 45(1):2215880. https:\/\/doi.org\/10.1080\/0886022X.2023.2215880","journal-title":"Ren Fail"},{"issue":"2","key":"4776_CR22","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1159\/000365935","volume":"40","author":"M Konarzewski","year":"2014","unstructured":"Konarzewski M, Szolkiewicz M, Sucajtys-Szulc E, Blaszak J, Lizakowski S, Swierczynski J, Rutkowski B (2014) Elevated circulating PCSK-9 concentration in renal failure patients is corrected by renal replacement therapy. Am J Nephrol 40(2):157\u2013163. https:\/\/doi.org\/10.1159\/000365935","journal-title":"Am J Nephrol"},{"key":"4776_CR23","doi-asserted-by":"publisher","first-page":"6677012","DOI":"10.1155\/2021\/6677012","volume":"2021","author":"E Dounousi","year":"2021","unstructured":"Dounousi E, Tellis C, Pavlakou P, Duni A, Liakopoulos V, Mark PB, Papagianni A, Tselepis AD (2021) Association between PCSK9 levels and markers of inflammation, oxidative stress, and endothelial dysfunction in a population of nondialysis chronic kidney disease patients. Oxid Med Cell Longev 2021:6677012. https:\/\/doi.org\/10.1155\/2021\/6677012","journal-title":"Oxid Med Cell Longev"},{"key":"4776_CR24","doi-asserted-by":"publisher","first-page":"1384523","DOI":"10.3389\/fcvm.2024.1384523","volume":"11","author":"Y Ma","year":"2024","unstructured":"Ma Y, Fan H, Mi W, Ma J, Deng Y, Song Y, Li X (2024) Proprotein convertase subtilisin\/kexin type 9 inhibitors protect against contrast-associated acute kidney injury in patients with atherosclerotic cardiovascular disease. Front Cardiovasc Med 11:1384523. https:\/\/doi.org\/10.3389\/fcvm.2024.1384523","journal-title":"Front Cardiovasc Med"},{"key":"4776_CR25","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/j.cca.2022.01.006","volume":"527","author":"X Su","year":"2022","unstructured":"Su X, Peng H, Chen X, Wu X, Wang B (2022) Hyperlipidemia and hypothyroidism. Clin Chim Acta 527:61\u201370. https:\/\/doi.org\/10.1016\/j.cca.2022.01.006","journal-title":"Clin Chim Acta"},{"issue":"10","key":"4776_CR26","doi-asserted-by":"publisher","first-page":"2119","DOI":"10.1038\/s41401-024-01305-9","volume":"45","author":"WZ Wang","year":"2024","unstructured":"Wang WZ, Liu C, Luo JQ, Lei LJ, Chen MH, Zhang YY, Sheng R, Li YN, Wang L, Jiang XH, Xiao TM, Zhang YH, Li SW, Wu YX, Xu Y, Xu YN, Si SY (2024) A novel small-molecule PCSK9 inhibitor E28362 ameliorates hyperlipidemia and atherosclerosis. Acta Pharmacol Sin 45(10):2119\u20132133. https:\/\/doi.org\/10.1038\/s41401-024-01305-9","journal-title":"Acta Pharmacol Sin"},{"issue":"1","key":"4776_CR27","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.1161\/ATVBAHA.123.320391","volume":"45","author":"Z Peng","year":"2025","unstructured":"Peng Z, Lv SJ, Chen H, Rao H, Guo Z, Wan Q, Yang J, Zhang Y, Liu DP, Chen HZ, Wang M (2025) Disruption of PCSK9 suppresses inflammation and attenuates abdominal aortic aneurysm formation. Arterioscler Thromb Vasc Biol 45(1):e1\u2013e14. https:\/\/doi.org\/10.1161\/ATVBAHA.123.320391","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"4776_CR28","doi-asserted-by":"publisher","DOI":"10.3390\/antiox11030569","author":"V Cammisotto","year":"2022","unstructured":"Cammisotto V, Baratta F, Simeone PG, Barale C, Lupia E, Galardo G, Santilli F, Russo I, Pignatelli P (2022) Proprotein convertase subtilisin kexin type 9 (PCSK9) beyond lipids: the role in oxidative stress and thrombosis. Antioxidants. https:\/\/doi.org\/10.3390\/antiox11030569","journal-title":"Antioxidants"},{"issue":"6","key":"4776_CR29","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1016\/j.diabet.2017.07.009","volume":"43","author":"B Cariou","year":"2017","unstructured":"Cariou B, Guerin P, Le May C, Letocart V, Arnaud L, Guyomarch B, Pichelin M, Probst V (2017) Circulating PCSK9 levels in acute coronary syndrome: results from the PC-SCA-9 prospective study. Diabetes Metab 43(6):529\u2013535. https:\/\/doi.org\/10.1016\/j.diabet.2017.07.009","journal-title":"Diabetes Metab"},{"issue":"1","key":"4776_CR30","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1186\/s12933-023-01948-8","volume":"22","author":"M Ruscica","year":"2023","unstructured":"Ruscica M, Macchi C, Giuliani A, Rizzuto AS, Ramini D, Sbriscia M, Carugo S, Bonfigli AR, Corsini A, Olivieri F, Sabbatinelli J (2023) Circulating PCSK9 as a prognostic biomarker of cardiovascular events in individuals with type 2 diabetes: evidence from a 16.8-year follow-up study. Cardiovasc Diabetol 22(1):222. https:\/\/doi.org\/10.1186\/s12933-023-01948-8","journal-title":"Cardiovasc Diabetol"},{"key":"4776_CR31","doi-asserted-by":"publisher","first-page":"5319","DOI":"10.2147\/JIR.S334246","volume":"14","author":"X Zhao","year":"2021","unstructured":"Zhao X, Song L, Wang Y, Li J, Zhou J, Chen R, Liu C, Zhou P, Sheng Z, Chen Y, Zhao H, Yan H (2021) Proprotein convertase subtilisin\/kexin type 9 and systemic inflammatory biomarker pentraxin 3 for risk stratification among STEMI patients undergoing primary PCI. J Inflamm Res 14:5319\u20135335. https:\/\/doi.org\/10.2147\/JIR.S334246","journal-title":"J Inflamm Res"},{"issue":"1","key":"4776_CR32","doi-asserted-by":"publisher","first-page":"3113","DOI":"10.1038\/s41598-018-35773-x","volume":"9","author":"Z Zhang","year":"2019","unstructured":"Zhang Z, Wei TF, Zhao B, Yin Z, Shi QX, Liu PL, Liu LF, Liu L, Zhao JT, Mao S, Rao MM, Wang SL, Chen YD (2019) Sex differences associated with circulating PCSK9 in patients presenting with acute myocardial infarction. Sci Rep 9(1):3113. https:\/\/doi.org\/10.1038\/s41598-018-35773-x","journal-title":"Sci Rep"},{"key":"4776_CR33","doi-asserted-by":"publisher","DOI":"10.5041\/RMMJ.10443","author":"FM Kajingulu","year":"2021","unstructured":"Kajingulu FM, Lepira FB, Nkodila AN, Makulo JR, Mokoli VM, Ekulu PM, Bukabau JB, Nlandu YM, Longo AL, Nseka NM, Sumaili EK (2021) Circulating proprotein convertase Subtilisin\/Kexin Type 9 levels predict future cardiovascular event risks in hemodialyzed black African patients. Rambam Maimonides Med J. https:\/\/doi.org\/10.5041\/RMMJ.10443","journal-title":"Rambam Maimonides Med J"},{"key":"4776_CR34","doi-asserted-by":"publisher","DOI":"10.3390\/jcm9010244","author":"HS Hwang","year":"2020","unstructured":"Hwang HS, Kim JS, Kim YG, Lee SY, Ahn SY, Lee HJ, Lee DY, Lee SH, Moon JY, Jeong KH (2020) Circulating PCSK9 level and risk of cardiovascular events and death in hemodialysis patients. J Clin Med. https:\/\/doi.org\/10.3390\/jcm9010244","journal-title":"J Clin Med"},{"issue":"9","key":"4776_CR35","doi-asserted-by":"publisher","DOI":"10.1111\/eci.14235","volume":"54","author":"C Torino","year":"2024","unstructured":"Torino C, Carbone F, Pizzini P, Mezzatesta S, D\u2019Arrigo G, Gori M, Liberale L, Moriero M, Michelauz C, Fre F, Isoppo S, Gavoci A, La Rosa F, Scuricini A, Tirandi A, Ramoni D, Mallamaci F, Tripepi G, Montecucco F, Zoccali C (2024) Proprotein convertase subtilisin\/kexin type 9 (PCSK9) and clinical outcomes in dialysis patients. Eur J Clin Invest 54(9):e14235. https:\/\/doi.org\/10.1111\/eci.14235","journal-title":"Eur J Clin Invest"}],"container-title":["International Urology and Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11255-025-04776-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11255-025-04776-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11255-025-04776-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,27]],"date-time":"2026-04-27T13:42:05Z","timestamp":1777297325000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11255-025-04776-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,20]]},"references-count":35,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2026,5]]}},"alternative-id":["4776"],"URL":"https:\/\/doi.org\/10.1007\/s11255-025-04776-9","relation":{},"ISSN":["1573-2584"],"issn-type":[{"value":"1573-2584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,20]]},"assertion":[{"value":"18 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 October 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that there are no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}},{"value":"The Ethics Committee of Handan Central Hospital approved this study; then the subjects provided informed consent.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval and consent to participate"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}}]}}